Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...
Gilead Sciences received accelerated approval for a chronic hepatitis delta virus treatment from the Food and Drug Administration. The FDA said the Hepcludex treatment, known also as bulevirtide-gmod, ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ...
Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) shares rose 2.5% Friday after the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta ...
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
SPYD's simplistic yield-focused strategy lacks robust quality filters, resulting in larger drawdowns and inferior ...
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver ...
Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that ...
Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 -- Builds on completed Phase 1a study and ongoing development in HDV - SOUTH SAN FRANCISCO, ...
The FDA approved Hepcludex injection for the treatment of chronic hepatitis D infection in adults without cirrhosis or with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results